These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23927662)

  • 1. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.
    Stangel M; Linker RA
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):355-62. PubMed ID: 23927662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
    Matolcsi J; Rózsa C
    Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fumaric acid ester BG-12: a new option in MS therapy.
    Lee DH; Stangel M; Gold R; Linker RA
    Expert Rev Neurother; 2013 Aug; 13(8):951-8. PubMed ID: 23944289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.
    Venci JV; Gandhi MA
    Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study.
    Kita M; Fox RJ; Phillips JT; Hutchinson M; Havrdova E; Sarda SP; Agarwal S; Kong J; Zhang A; Viglietta V; Sheikh SI; Seidman E; Dawson KT
    Mult Scler; 2014 Feb; 20(2):253-7. PubMed ID: 24150778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.
    Linker RA; Gold R
    Curr Neurol Neurosci Rep; 2013 Nov; 13(11):394. PubMed ID: 24061646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl fumarate for relapsing-remitting multiple sclerosis.
    Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.
    Kappos L; Gold R; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Sarda SP; Agarwal S; Zhang A; Sheikh SI; Seidman E; Dawson KT
    Mult Scler; 2014 Feb; 20(2):243-52. PubMed ID: 24150779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Burness CB; Deeks ED
    CNS Drugs; 2014 Apr; 28(4):373-87. PubMed ID: 24623127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
    Fox RJ; Kita M; Cohan SL; Henson LJ; Zambrano J; Scannevin RH; O'Gorman J; Novas M; Dawson KT; Phillips JT
    Curr Med Res Opin; 2014 Feb; 30(2):251-62. PubMed ID: 24131282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl fumarate for treating relapsing multiple sclerosis.
    Sheremata W; Brown AD; Rammohan KW
    Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl fumarate (Tecfidera) for multiple sclerosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1418):45-7. PubMed ID: 24662841
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
    Havrdova E; Hutchinson M; Kurukulasuriya NC; Raghupathi K; Sweetser MT; Dawson KT; Gold R
    Expert Opin Pharmacother; 2013 Oct; 14(15):2145-56. PubMed ID: 23971970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BG-12 in multiple sclerosis.
    Phillips JT; Fox RJ
    Semin Neurol; 2013 Feb; 33(1):56-65. PubMed ID: 23709213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fumarate for relapsing-remitting multiple sclerosis.
    Sorensen PS; Sellebjerg F
    Lancet; 2008 Oct; 372(9648):1447-8. PubMed ID: 18970966
    [No Abstract]   [Full Text] [Related]  

  • 18. [Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects].
    Stangel M; Moharregh-Khiabani D; Linker RA; Gold R
    Nervenarzt; 2008 Feb; 79(2):212-7. PubMed ID: 18210050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
    Kappos L; Gold R; Miller DH; Macmanus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Yang M; Eraksoy M; Meluzinova E; Rektor I; Dawson KT; Sandrock AW; O'Neill GN;
    Lancet; 2008 Oct; 372(9648):1463-72. PubMed ID: 18970976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl fumarate for multiple sclerosis.
    Papadopoulou A; D'Souza M; Kappos L; Yaldizli O
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1603-12. PubMed ID: 21067468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.